2019 冠状病毒病后遗留后遗症在风湿性疾病患者中的负担。

The Burden of Post-Acute Sequelae of Coronavirus Disease 2019 in Individuals with Rheumatic Diseases.

机构信息

Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Rheumatology & Allergy Clinical Epidemiology Research Center, Mongan Institute, Massachusetts General Hospital, Boston, MA, USA.

出版信息

Rheum Dis Clin North Am. 2025 Feb;51(1):15-28. doi: 10.1016/j.rdc.2024.08.003. Epub 2024 Oct 11.

DOI:10.1016/j.rdc.2024.08.003

PMID:39550103

Abstract

The long-term impacts of coronavirus disease 2019 (COVID-19), or post-acute sequelae of COVID-19 (PASC), are especially pertinent for individuals with systemic autoimmune rheumatic diseases, who are at higher risk of developing COVID-19 infection, complications of acute infection, and possibly PASC. Severity of acute COVID-19 infection, female sex, comorbidities, and immunosuppressive medications impact the risk of PASC in this population. The etiology of PASC remains poorly defined, and the diagnosis is clinical, with symptoms that can overlap with those of rheumatic diseases. A better understanding of the physiologic mechanisms could help to more clearly define PASC and to guide the development of targeted treatments.

摘要

新型冠状病毒病 2019（COVID-19）的长期影响，即 COVID-19 后的后遗症（PASC），对患有系统性自身免疫性风湿病的个体尤其相关，这些人患 COVID-19 感染、急性感染并发症以及可能的 PASC 的风险更高。急性 COVID-19 感染的严重程度、女性、合并症和免疫抑制药物都会影响该人群发生 PASC 的风险。PASC 的病因仍不清楚，其诊断为临床诊断，症状可能与风湿病的症状重叠。更好地了解生理机制可能有助于更清楚地定义 PASC，并指导靶向治疗的开发。